Development and Qualification of a Physiologically Based Pharmacokinetic Model of Finasteride and Minoxidil Following Scalp Application

J Pharm Sci. 2021 May;110(5):2301-2310. doi: 10.1016/j.xphs.2021.02.016. Epub 2021 Feb 18.

Abstract

In this study, we aimed to develop and qualify a PBPK model for scalp application using two drugs with marked differences in physicochemical properties and PK profiles. The parameters related to scalp physiology, drug PK, and formulations were incorporated into a Multi-Phase and Multi-Layer (MPML) Mechanistic Dermal Absorption (MechDermA) model within the Simcyp® Simulator V17. The finasteride PBPK model was linked to its effect on dihydrotestosterone (DHT) levels in plasma and scalp using an indirect response model. Predicted PK (and PD for finasteride) profiles and parameters were compared against the clinically reported data and justified by visual predictive checks and two-fold error criteria for model verification. The PBPK/PD model for finasteride reasonably demonstrated an ability to predict its respective PK and PD profiles, and parameters following scalp application under various clinical scenarios. Using the same scalp physiological input parameters, the minoxidil PBPK model was then developed and satisfactorily qualified with independent clinical datasets. Collectively, these results suggested that the established PBPK model may have broader utility for other topical formulations intended for scalp application.

Keywords: Absorption, Distribution, Metabolism, and Excretion (ADME); Physiologically Based Pharmacokinetic (PBPK) modeling; SimCyp PBPK modeling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Finasteride*
  • Minoxidil*
  • Models, Biological
  • Scalp

Substances

  • Finasteride
  • Minoxidil